Authors: Aerssens, J Raeymaekers, P Lilienfeld, S Geerts, H Konings, F Parys, W

Citation: J. Aerssens et al., APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease, DEMENT G C, 12(2), 2001, pp. 69-77

Authors: Feldman, H Sauter, A Donald, A Gelinas, I Gauthier, S Torfs, K Parys, W Mehnert, A

Citation: H. Feldman et al., The Disability Assessment for Dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease, ALZ DIS A D, 15(2), 2001, pp. 89-95

Authors: Lilienfeld, S Parys, W

Citation: S. Lilienfeld et W. Parys, Galantamine: Additional benefits to patients with Alzheimer's disease, DEMENT G C, 11, 2000, pp. 19-27

Authors: Parys, W

Citation: W. Parys, Development of Reminyl (R) (galantamine), a novel acetylcholinesterase inhibitor, for the treatment of Alzheimer's disease, ALZHEIM REP, 1, 1998, pp. S19-S20